CN Patent

CN104136451A — 具有构象限制的单体的核酸化合物的合成和用途

Assigned to Marina Biotech Inc · Expires 2014-11-05 · 12y expired

What this patent protects

用于制备核酸化合物的构象限制的核单体(CRN)的合成和用途。以高收率和多克规模制备用于治疗模式的核酸化合物的核单体的方法，所述治疗模式通过上调或下调细胞中的基因和其它基于核酸的调节系统的表达而用于治疗或预防疾病或病症。

USPTO Abstract

用于制备核酸化合物的构象限制的核单体(CRN)的合成和用途。以高收率和多克规模制备用于治疗模式的核酸化合物的核单体的方法，所述治疗模式通过上调或下调细胞中的基因和其它基于核酸的调节系统的表达而用于治疗或预防疾病或病症。

Drugs covered by this patent

Patent Metadata

Patent number: CN104136451A
Jurisdiction: CN
Classification: —
Expires: 2014-11-05
Drug substance claim: No
Drug product claim: No
Assignee: Marina Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.